Vineet Laboratories Limited

BSE: VINEETLAB543298ISIN INE505Y01010

Healthcare
Pharmaceuticals

BSE listing

Share price

₹36.45+0.44 (+1.22%)

as of 18 Sep 2026

52W high: ₹51.84
52W low: ₹28.00
Off 52W high: -29.69%
1M return: -3.88%
3M return: +7.08%
6M return: +23.85%
1Y return: +3.29%
20D avg volume: 21,012
50 DMA: ₹37.52
200 DMA: ₹35.36

Key ratios Standalone

Market cap: ₹70.01 Cr
Current price: ₹36.45
52W high / low: ₹51.84 / ₹28.00
Face value: ₹10.00
P/E: 43.39
P/B: 2.28
EPS (TTM): ₹0.84
Book value / share: ₹15.99
ROE: 5.21%
ROCE: 10.70%
Operating margin: 13.37%
Net margin: 6.45%
Debt / equity: 0.99
Net debt: ₹28.63 Cr
Interest cover: 1.26
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 308.3 days

Financials

Metric	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	18.89	15.65	17.42	7.44	14.08	—
	0.03	0.05	0.01	0.02	1.38	—
	17.93	14.88	17.06	8.36	26.68	—
	23.07	9.72	17.09	12.01	12.71	—
	0.00	0.00	0.00	0.00	0.00	—
	1.20	1.04	0.80	1.06	1.35	—
	0.99	1.09	2.19	0.61	0.90	—
	0.54	0.63	0.63	0.63	0.66	—
	2.79	2.34	1.63	1.45	3.20	—
	0.99	0.82	0.37	-0.90	-11.22	—
	0.00	0.00	0.00	0.00	0.00	—
	0.99	0.82	0.37	-0.90	-11.22	—
	0.27	-0.03	-0.03	-0.04	-0.70	—
	1.22	0.85	0.40	-0.87	-10.53	—
	0.43	0.92	0.43	-0.94	-11.42	—
Key metrics
	2.52	2.54	3.19	0.34	-9.66	—
	13.30%	16.20%	18.30%	4.60%	-68.60%	—
	6.50%	5.40%	2.30%	-11.70%	-74.80%	—
	3.40%	—	11.30%	—	-51.20%	—
	34.20%	—	—	—	—	—
	111.60%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	59.40	59.40	75.00	—
	0.11	0.10	1.99	—
	58.23	58.22	97.76	—
	61.89	61.88	63.77	—
	0.00	0.00	0.00	—
	4.10	4.10	5.34	—
	4.88	4.89	3.98	—
	2.43	2.41	2.50	—
	8.21	8.22	15.70	—
	1.28	1.28	-20.78	—
	0.00	0.00	0.00	—
	1.28	1.28	-20.78	—
	0.17	0.17	-0.58	—
	1.60	1.60	-20.19	—
	0.84	1.00	-21.90	—
Key metrics
	8.59	8.58	-14.30	—
	14.46%	14.40%	-19.10%	—
	2.69%	2.70%	-26.90%	—
	—	10.70%	-83.40%	—
	—	-20.80%	—	—
	—	107.90%	—	—
	—	-13.44	10.44	—
	—	-7.65	-0.57	—
	—	0.99	2.73	—
	—	28.63	39.74	—
	—	308.3	144.1	—
Balance sheet
	—	124.78	94.54	—
	—	98.83	67.39	—
	—	16.70	0.31	—
	—	11.40	13.25	—
	—	64.09	49.97	—
	—	6.26	0.00	—
	—	24.24	25.46	—
	—	25.33	33.61	—
	—	67.28	74.39	—
	—	45.33	40.05	—
	—	35.12	36.26	—
	—	10.21	3.79	—
	—	45.60	14.65	—
Cash flow
	—	-12.24	11.49	—
	—	-1.11	-3.18	—
	—	29.74	-8.23	—
	—	1.20	1.05	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 6.00%

Holder	Type	Holding	Previous	Change
ARJUN AGGARWAL	Public	11.35%	—	—
GADDAM VENKATA RAMANA	Promoter	2.46%	—	—
MADHU NALAJALA	Public	2.40%	—	—
RAJESH PODDAR	Public	2.15%	—	—
PALLOLI RAMA CHANDRA REDDY	Public	1.86%	—	—
ISWARYA GAJJALA	Public	1.62%	—	—
Sudha Madhu Sudhan Reddy	Public	1.61%	—	—
ANASUYA GORLA	Public	1.58%	—	—
RAJENDRA AGRAWAL	Public	1.57%	—	—
AJAY AGRAWAL	Public	1.53%	—	—
SUREKHA NAGA LAKSHMI PENDELA	Public	1.51%	—	—
JYOTI AGARWAL	Public	1.39%	—	—
SATYANARAYANA RAJU BHUPATHIRAJU	Promoter	0.69%	—	—
A PRABHAKAR RAJU	Promoter	0.50%	—	—
A SRINIVASA RAJU	Promoter	0.49%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

We wish you to inform you that Rigistrar of Companies, Hyderabad has granted an extension of two months for holding the 10th Annual General Meeting of the company in respect of financial ....19 Sep 2026 · Company Update / General
Updated Financial Results for the Quarter and Finacial year ended 31st March 202629 Aug 2026 · Result / Financial Results
The Board of Director of the company in its meeting held on August 25 2026 Approved the Audited Standalone Financial Results for the fourth quarter and the financial year ended on 31st ....25 Aug 2026 · Result / Financial Results
The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has: Approved the Audited Standalone Financial Results of the Company for the fourth quarter and ....25 Aug 2026 · Board Meeting / Outcome of Board Meeting
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve the Audited Standalone ....20 Aug 2026 · Board Meeting / Board Meeting
Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 202614 Aug 2026 · Company Update / Monitoring Agency Report
We are hereby submitting the compliance Certificate issued by Venture Capital and Corporate Inveatments Private Limited30 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are hereby informed that Mr. Gaddam Venkata Ramana ( DIN:00031873) has ceased to hold office of Managing Director of Vineet Laboratories with effect form July 21 2026. It further clarified ....21 Jul 2026 · Company Update / Resignation of Managing Director
Appointment of Rajesh Kumar Kathulla as an Additional Director (Executive Catagory) of the company with effect from 11th day of June, 202621 Jul 2026 · Company Update / Change in Management
Intimation regarding diferment of Board Meeting16 Jul 2026 · Company Update / General
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/07/2026 ,inter alia, to consider and approve Audited Standalone Financial Results11 Jul 2026 · Board Meeting / Board Meeting
Outcome of Board Meeting Held on May 30,2026 Deferment of Consideration of Audited Standalone Financial Results30 May 2026 · Company Update / General
We are hereby submitting the resignation of Company Secretary.29 May 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Standalone ....26 May 2026 · Board Meeting / Board Meeting
Please find the attached Monitoring Agency Report issued by Crisil Rating Limited for the quarter ended March 31, 202615 May 2026 · Company Update / Monitoring Agency Report
We are hereby submitting the certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with Regulation 74(5) of SEBI (Depositories and Participants) ....21 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Trading window for dealing in securities of the Company will remain closed from 01st April, 2026 till 48 hours after announcement of Standalone Audited Financial results for the Fourth ....30 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
We enclose herewith the copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers ....16 Feb 2026 · Company Update / Newspaper Publication
The Board of Directors in its meeting held today i.e on February 14, 2026 has considered and approved the Unaudited Standalone Financial Results along with the Limited Review Report submitted ....14 Feb 2026 · Result / Financial Results
The Board of Directors of the company in its meeting held today i.e., Saturday, February 14, 2026 has: considered and approved the unaudited standalone financial results of the company ....14 Feb 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arjun Aggarwal11 Feb 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Vineet Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve unaudited standalone financial ....10 Feb 2026 · Board Meeting / Board Meeting
We are hereby submitting the Voting results of Extra-Ordinary General Meeting of Vineet Laboratories Limited held on Saturday, February 07, 2026.7 Feb 2026 · AGM/EGM / EGM
We are hereby submitting the proceedings of EGM of Vineet Laboratories Limited held on Saturday, February 07, 2026 through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).7 Feb 2026 · AGM/EGM / EGM
We are hereby submitting the trading approvals received from BSE and NSE vide their letters dated February 04, 2026 for the Equity shares allotted under Rights Issue of the Company.4 Feb 2026 · Company Update / General
We are submitting copies of advertisements published by the Company today i.e. February 02, 2026, in respect of matters relating to Basis of Allotment of Rights Issue of Equity Shares of ....4 Feb 2026 · Company Update / Newspaper Publication
We would like to inform that the Rights Issue Committee of the Board of Directors of Vineet Laboratories Limited ("the Company") has today i.e. February 02, 2026, considered and approved ....2 Feb 2026 · Company Update / Meeting Updates
We are hereby submitting the copies of the Addendum to the Letter of Offer dated December 17, 2025 published today in the following newspapers: 1. Financial Express (English National Daily ....14 Jan 2026 · Company Update / Newspaper Publication
We are hereby submitting the Newspaper publication made in Financial Express and Nava Telangana regarding the notice of Extra-Ordinary General Meeting of the Company to be held on February 07, 202613 Jan 2026 · Company Update / Newspaper Publication
The Rights Issue Committee of the Board of Directors in its meeting held on January 13, 2026, has decided to extend the "Last date for On Market Renunciation" and the "Issue Closing date" ....13 Jan 2026 · Company Update / Meeting Updates
The Extra-Ordinary General Meeting of the Company is being conducted on Saturday, February 07, 2026 at 11.00 A.M. We are hereby submitting the notice of the EGM.12 Jan 2026 · AGM/EGM / EGM
We are hereby submitting the certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) ....9 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Board of Directors of the company in its meeting held today i.e., on Wednesday, January 07, 2026 has approved: 1. Notice of Extra - Ordinary General Meeting to obtain the approval ....7 Jan 2026 · Others / Outcome without intimation
We are hereby submitting the Newspaper Advertisements published before the date of opening of the Rights Issue as required under Regulation 84(1) of SEBI (ICDR) Regulations, 2018.29 Dec 2025 · Company Update / Newspaper Publication
The Trading Window for dealing in the securities of the Company will remain closed from 01st January, 2026 till 48 hours after the announcement of Standalone Un-audited Financial results ....27 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
The Company is hereby submitting the Letter of Offer for Rights Issue.20 Dec 2025 · Company Update / Raising of Funds
The Company has made necessary arrangements with NSDL and CDSL for credit of Rights Entitlements in dematerialized form in the demat accounts of the Eligible Equity Shareholders.17 Dec 2025 · Company Update / General
We hereby inform that the Rights Issue Committee of the Board in its meeting held today, i.e., December 17, 2025 has inter alia considered and approved the Rights Issue Price, Rights Issue ....17 Dec 2025 · Corp. Action / Bonds / Right issue
We hereby inform that the Rights Issue Committee in its meeting held today, December 17, 2025 has approved the Record Date for the proposed Rights Issue to be Tuesday, December 23, 2025.17 Dec 2025 · Corp. Action / Record Date
We hereby inform that the Rights Issue Committee of the Board in its meeting held today i.e. on December 17, 2025 has inter alia considered and approved the Rights Issue Price, Entitlement ....17 Dec 2025 · Company Update / Raising of Funds

Corporate actions

Purpose	Ex date	Record date	Payment date
Right Issue of Equity Shares	23 Dec 2025	23 Dec 2025	—

Board meetings

25 Aug 2026 Board Meeting - Financial Results